ClinicalTrials.gg
RecruitingNCT06178198RESCUEUpdated Aug 20, 2026

Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma

A Phase 2 interventional study of Ablative radioembolization using Yttrium-90 resin microspheres in Hepatocellular Carcinoma, sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Seoul National University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital — 9 open to participants now, 14 under way, none of them phase 3. Carcinoma, Hepatocellular · Seoul National University Hospital.

Planned enrollment
39th of 52
30 · median 85
Started
2023
with 4 others
Phase 2
12 of 61
3 open now
Primary completion
2026-11
later than 7 of 13 live
Registered
52nd of 61
by date

Among the 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital, this one is the 39th largest by planned enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2023, is one of 12 in phase 2, reaches primary completion later than 7 of the 13 other live ones, and was the 52nd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

9 of the 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Carcinoma, Hepatocellular by Seoul National University Hospital, or all of them as a file.
02

Study summary

The RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in patients with large hepatocellular carcinoma (greater than 8 cm) who maintain good liver function.

Read the detailed description

Patients presenting with large hepatocellular carcinoma (greater than 8 cm), whether accompanied by satellite nodules or not, but retaining good liver function, will undergo ablative radioembolization utilizing Yttrium-90 resin microspheres. This approach is designed to deliver an ablative dose to both tumors and the surrounding liver (i.e., margin) with curative intent, while preserving over 30% of the non-tumorous liver volume. The efficacy and safety of this treatment will be evaluated over a period of two years and 90 days, respectively.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Hepatocellular Carcinoma
  • Radioembolization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 and over.
  2. Patients diagnosed with hepatocellular carcinoma histologically and/or radiologically (LI-RADS 4 or 5).
  3. Patients with no more than five lesions in dynamic contrast-enhanced CT or MRI, and the largest tumor diameter exceeding 8 cm.
  4. Patients without vascular invasion and bile duct invasion in dynamic contrast-enhanced CT or MRI.
  5. Patients with no extrahepatic in lung CT and contrast-enhanced abdominal CT or MRI.
  6. Patients with no prior treatment for liver cancer.
  7. class A.
  8. performance status of 1 or less.
  9. Patients with no major organ dysfunction according to blood tests performed within one month of study enrollment.

    1. Leukocytes ≥ 2,500/µL and ≤ 12,000/µL
    2. ≥ 1,500 /mm\^3
    3. ≥ 8.0 g/dL (transfusion allowed to meet this criterion)
    4. Total ≤ 3.0 mg/dL
    5. ≥ 50,000/µL
    6. ≤ 2.0 for patients not taking anticoagulants
    7. ≤ 200 IU/L (i.e., ≤ 5X upper normal limit)
    8. ALT ≤ 200 IU/L (i.e., ≤ 5X upper normal limit)
    9. ALP ≤ 575 IU/L (i.e., ≤ 5X upper normal limit)
    10. Creatinine ≤ 2.0 mg/dL
  10. Patients with a of more than 3 months.
  11. Patients who have adequately understood the clinical trial and consented in writing.
  12. Non-pregnant women of .

Exclusion criteria

Exclusion Criteria:

  1. Patients who are not suitable for ablative radioembolization as indicated by pre-treatment testing with macro-aggregated albumin labeled with technetium-99 (99mTc-MAA) for radioembolization.

    1. Cases where the estimated lung dose exceeds 15 Gy when 150 Gy of absorbed dose is administered to the tumor based on the partition method.
    2. Cases with severe hepatic artery-portal vein shunting that might lead to irradiation of the non-tumorous liver segments.
  2. Patients whose volume of non-tumorous liver not included in the treatment area is less than 30% of the total non-tumorous liver volume.
  3. Patients scheduled to use immunotherapy irrespective of the response to radioembolization.
  4. Patients who have had active cancer within the last two years prior to the clinical trial participation.
  5. Patients who have undergone surgery or procedures related to the bile duct.
  6. Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Ablative radioembolization for large HCC

    Yttrium-90 resin microspheres (SIR-Sphere, SIRTEX) will be administered to cover the main tumor, satellite nodules, and margin.

    Procedure: Ablative radioembolization using Yttrium-90 resin microspheres

Interventions

  • ProcedureAblative radioembolization using Yttrium-90 resin microspheres

    Based on 99mTc-MAA mapping, a partition model (multi-compartment MIRD) is employed to plan for a radiation dose of 400 (± 30%) to the tumor. If delivering this dose to the tumor is challenging due to lung dose limitations, the maximum feasible dose is administered to the tumor while maintaining the estimated lung dose below 15 Gy. While treating the entire tumor with a single high-dose radioembolization session is preferred, if necessary due to considerations like estimated lung dose, the treatment can be divided into two sessions, keeping the cumulative lung dose below 25 Gy. For any methods not covered in this discussion, refer to the SIR-Sphere user manual by Sirtex.

06

What researchers measure

Primary outcomes

  1. Objective response rate according to localized mRECIST

    The number of patients with partial or complete response as the best local response divided by the total number of participants

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  2. Duration of response according to localized mRECIST

    The time from first documentation of partial or complete response to the first documentation of progressive disease, death due to any cause, or receipt of subsequent anticancer treatment, whichever comes first

    Time frame: Time of response up to progression, subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

Secondary outcomes

  1. Objective response rate according to mRECIST.

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  2. Duration of response according to mRECIST

    Time frame: Time of response up to progression, subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  3. 2-year restricted mean duration of response according to localized mRECIST and mRECIST

    Time frame: Time of response up to progression, subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or 24 months after the initial treatment

  4. Complete response rate according to localized mRECIST and mRECIST

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  5. Duration of complete response according to localized mRECIST and mRECIST

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  6. 2-year restricted mean DoCR (RMDoCR) according to localized mRECIST and mRECIST

    Time frame: Time of complete response up to progression, subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or 24 months after the initial treatment

  7. Best response within 2-years according to localized mRECIST and mRECIST

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  8. Time to best response according to localized mRECIST and mRECIST

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  9. Time to progression according to localized mRECIST and mRECIST

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  10. Overall survival

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  11. 2-year restricted mean survival time of overall survival

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or 24 months the initial treatment

  12. Progression-free survival

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  13. Hepatic progression-free survival (HPFS)

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  14. Pathological necrosis rate (%) after curative resection or liver transplantation

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  15. Time to subsequent HCC treatment

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  16. Reason for subsequent HCC treatment

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  17. Rate for conversion to curative resection and liver transplantation

    Time frame: Time of treatment up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (24 months after the last patient is enrolled)

  18. Adverse event and serious adverse event

    Common Terminology Criteria for Adverse Events v5.0

    Time frame: Time of treatment up to 90 days after the initial treatment or subsequent anticancer treatment, whichever comes first

  19. Changes in Child-Pugh class

    Time frame: Baseline up to 90 days after the initial treatment or subsequent anticancer treatment, whichever comes first

  20. Changes in ALBI (albumin-bilirubin) grade

    Time frame: Baseline up to 90 days after the initial treatment or subsequent anticancer treatment, whichever comes first

  21. Changes in MELD (model for end-stage liver disease) score

    Time frame: Baseline up to 90 days after the initial treatment or subsequent anticancer treatment, whichever comes first

  22. Changes in ECOG (Eastern Cooperative Oncology Group) performance status scale

    0 (fully active) to 5 (dead)

    Time frame: Baseline up to 90 days after the initial treatment or subsequent anticancer treatment, whichever comes first

  23. Changes in health-related quality of life

    EORTC QLQ-C30 and HCC18

    Time frame: Baseline up to 90 days after the initial treatment or subsequent anticancer treatment, whichever comes first

  24. Changes in regional liver function

    99mTc-MAA hepatobiliary scan with SPECT-CT

    Time frame: Baseline up to 180 days after the initial treatment or subsequent anticancer treatment, whichever comes first

Other outcomes

  1. Pre-treatment dosimetry based on 99mTc-MAA SPECT-CT

    Time frame: Baseline

  2. Post-treatment dosimetry based on Y90 PET-CT

    Time frame: Within two days after the procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Levillain H, Bagni O, Deroose CM, Dieudonne A, Gnesin S, Grosser OS, Kappadath SC, Kennedy A, Kokabi N, Liu DM, Madoff DC, Mahvash A, Martinez de la Cuesta A, Ng DCE, Paprottka PM, Pettinato C, Rodriguez-Fraile M, Salem R, Sangro B, Strigari L, Sze DY, de Wit van der Veen BJ, Flamen P. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1570-1584. doi: 10.1007/s00259-020-05163-5. Epub 2021 Jan 12. PubMed 33433699 ↗
  • Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29. doi: 10.1016/S2468-1253(20)30290-9. Epub 2020 Nov 7. PubMed 33166497 ↗
  • Choi JW, Suh M, Paeng JC, Kim JH, Kim HC. Radiation Major Hepatectomy Using Ablative Dose Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma 5 cm or Larger. J Vasc Interv Radiol. 2024 Feb;35(2):203-212. doi: 10.1016/j.jvir.2023.10.011. Epub 2023 Oct 21. PubMed 37866475 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 36 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 20, 2023
StartActual
Nov 8, 2023
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06178198
Responsible party
Jin Woo Choi (Associate Professor, Seoul National University Hospital) — Principal investigator
First posted
Dec 20, 2023
Start date
Nov 8, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Aug 20, 2026

Study contacts

Jin Woo Choi, MD, PhD
Contact
jwchoi.med@snu.ac.kr
+82-220722584
Jin Woo Choi, MD, PhD
study chair · Seoul National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion